Loading...
Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis
EGFR (exon 19 and exon 21) mutations in patients with advanced non-small cell lung cancer (NSCLC) treated by EGFR-TKIs are associated with a better survival; while KRAS mutations predict a worse prognosis. However, there are divergent findings regarding the prognostic value of EGFR and KRAS mutation...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5464923/ https://ncbi.nlm.nih.gov/pubmed/28430611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15412 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|